Liftstream is an executive search recruitment company in the life sciences sector
eFFECTOR Therapeutics Secures New Series B Funding
eFFECTOR Therapeutics, an early-stage company focused on the discovery and development of small molecule cancer therapeutics in San Diego, has secured its Series B financing up to USD 56 million. The new funding came from Sectoral Asset Management, a new investor in the syndicate, as well as existing investors. Meanwhile, eFFECTOR Therapeutics appointed Maha Katabi, a partner from Sectoral, to its board of directors.
Bicycle Therapeutics raises $32m for oncology assets
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Astellas Ventures, Atlas Ventures, Bicycle Therapeutics, Cambridge Antibody Technology, Domantis, funding, London Biotech, One Nucleus, Oxford Biotech, Professor Christian Heinis, Rolf Gunther, Sir Greg Winter, SR One, SV Life Sciences, venture capital
Leave a comment
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment
Pharma marries VCs to give birth to Biotechs
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Amgen, Atlas Ventures, Avalon Ventures, biotech, Bruce Booth, celgene, collaborative business models, Francesco De Rubertis, Fund IX, GSK, Index Ventures, J&J, Johnson & Johnson, Kevin Johnson, Large Pharma, LSD, Nimbus Discovery, Novartis, Pangenetics, Paul Stoffels, pharma, Quanticel, R&D, Sanofi, Shire HGT, SR One, Third Rock Ventures, Tibotec, venture capital, Versant Ventures, Warp Drive Bio
Leave a comment
Genesis 2012 – The Debate on UK Biotech
Authored by Karl Simpson
Posted in Pharmaceutical business
Tagged Andrew J Pulkrabek, AstraZeneca, BIA, Biocity, BioLauncher, biotech, Biotech Clusters, BMS, Boston, Bristol-Myers Squibb, Cambridge, CEO, Clusters, Datamonitor, David Phillips, Enablers, genesis 2012, Genesis debate, Glen Crocker, Greer Deal, Industry, Kenneth Powell, King's Health Partners, Life Science, Life Science Investment Organisation, LifeScience Ventures, Liftstream, London, Lubor Gaal, Mark Treherne, Mission Therapeutics, NICE, Oxford, Prof. Sir Robert Lechler, Q-CHIP, Rowan Gardner, Shaun Grady, SR One, Steve Bates, UK, UKBIF
1 Comment